Valuation in 2016-2019
Invest in Ginkgo Bioworks
Please, log in or sign up to invest in Ginkgo Bioworks
Ginkgo Bioworks is a new lab that uses robotic systems to make an assembly line for churning out exotic life-forms. The company experiments with DNA and programs cells to create custom-made organisms for their clients. The synthetic organisms manufactured by Ginkgo Bioworks are used in a wide range of industrial and pharmaceutical applications.
Ginkgo builds on the premise of replacing technology with biology. Modified organisms from Ginkgo Bioworks streamline the production of perfumes, beverages, pesticides, and laundry detergent. For example, the extraction of rose oil from rose petals is expensive, but if you add the right genes to a yeast cell, you can get the real oil.
Ginkgo Bioworks outsources the manufacture of synthetic DNA from several biotechs. Building a custom-made organism with the right capabilities on a grand scale requires huge resources and rigorous lab testing, and that’s what Ginkgo actually does.
Founded by scientists from MIT in 2009, Ginkgo Bioworks has become a leader in synthetic biology with industrial applications. The company built the most advanced compiler and debugger of genetic code for accelerated engineering of new organisms. In the future Ginkgo Bioworks plans to create a biological platform to produce any compound that can be synthesized in a living organism.
A September 2020 Grounds Alerts report says that the global synthetic biology market is valued at $11 billion in 2018 and is expected to reach $55 billion by the end of 2025, at a CAGR of 24 % over the next five years.
For a long time scientists have been seeking to optimize the genetic engineering process. But Ginkgo Bioworks is the one biotech that actually succeeded in bulk experimentation. The company applies a rigorous design-build-test cycle and extreme automation of routine tasks to create organisms in a few months instead of years, if not decades.
Ginkgo Bioworks’ service enabled by its in-house software, robotic equipment and outsource manufacture represents the most impressive attempt at a technology revolution in a lab.
Long-term activity related risk. Zymergen, Thermo Fisher Scientific (TMO), Twist Bioscience (TWST) are seen as Ginkgo Bioworks’ biggest rivals. The competition may stunt the company’s development in the future.
The market may be overvalued. The synthetic biology market is comparably young – there is a chance that analysts and venture capitalists are overestimating the growth potential of this industry.
Ginkgo Bioworks hasn’t disclosed its financial performance. It is unknown if the company is currently profitable and if there’s any tendency toward profitability.
Ginkgo Bioworks has secured a total of $790 million from venture investors. Its last funding in September 2019 valued the company at $4.4 billion. Price per share is $150,19. Now Ginkgo shares on the OTC market are worth $138.6, which suggests a valuation of $4 billion.
Ginkgo Bioworks’ revenue comes from two channels. It produces living organisms on a scale and launches spinouts with corporate partners. Ginkgo partnered with Bayer to work on the plant microbiome to make nitrogen fertilizer available for plants, creates protein replacements with Motif Foodworks and produces cultured cannabinoids with Cronos. Such business model allows the company to scale up and create multiple growth opportunities in the future.
According to Forbes, Ginkgo's revenue doubled to $80 million in 2019 from $40 million the previous year. The company's projected revenue by the end of 2020 — $150 million, in 2021 — $200-300 million.
Similar biotech Twist Bioscience went public in 2018, with one share worth 14$. At the end of September 2020 its stock is $75. Twist Bioscience’s capitalization is $3.3 billion, its last year's revenue was $73 million. Shares are traded at a 45x P/S ratio, with slightly slower growth (56% year-on-year) as compared to Ginkgo.
Ginkgo’s projected capitalization, given it maintains the current multipliers, will amount to $9-12 billion on the public market. Bioworks IPO is expected in 2021. Potential return on investment is 150%.
United Traders analysts are in continuous search for OTC offers studying financial reporting, companies’ businesses, their future plans, analyzing them as potential acquisition targets or estimating prospective multifold capitalization increase as well as considering risks that may hinder business growth. The best ideas are offered to our investors.
As part of our service for purchasing shares on the OTC market, for its traders and investors United Traders buys units in funds that own equity stakes in private companies. These funds make early-stage investments in private companies or acquire equity stakes from employees of such companies.
United Traders will have shares at its disposal after the IPO. The shares can be sold after the established 6-month Lock-up period. Alternatively, the shares can be hedged for the above period. Prior to the company going public United Traders look for exit options in the OTC market. If we find a great offer, we sell the shares.
After the Lock-up period is over, the investment position will be automatically closed, and generated profits are credited to your account less the applicable UT fees. We offer an opportunity for investors with over $100,000 invested in a specific idea to search for a counterpart in the OTC market individually and to take profits before the company goes public and thereby exiting the trade prior to the Lock-up period expiration.
Although it is prohibited to sell shares within the Lock-Up period, our traders find ways to take profits for our investors using various financial instruments: forwards, options, short selling trades, etc.
For an investor the above means that the investment may be exited after paying a portion of its value, usually around 15% which is caused by highly-priced instruments used to close the position. To do so, you should press the respective button in your members area as soon as it becomes active.
The exiting process is similar to making a new investment. You submit a request, we execute it within 1 business day, and your investment is closed at the current exchange price.
3.5% of the share purchase amount. The fee is charged at confirmation of your investment bid.
0.5% of the share sell amount after the trade. The fee is charged at the investment exit.
20% of the profit gain. The fee is charged only if the trade is profitable at the time of exiting.
EARLY EXIT FEE
Usually a 15% fee is charged subject to the actual situation at the exchange. The fee is calculated individually for each investment.
WE ARE A RELIABLE PARTNER
Our risk managers will support you throughout the entire transaction life. You can also contact us by phone: +7 495 646-15-57 or 8 800 333-66-81, or visit our office for a detailed discussion.
Venture investing is very risky as they involve new or growing companies, and multifold increase in capitalization is expected. We select companies that already demonstrate strong financials and plan to go public soon. This approach allows limiting hyper-risks related to insolvency of new companies and substantially increasing profits as compared to investors who buy shares in a pre-IPO subscription.
LOW ENTRY THRESHOLD
To qualify for a pre-IPO subscription, one would need millions of dollars. We gathered a pool of traders and investors allowing everyone interested to join similar transactions with as much as $15.
United Traders is experienced in minimizing risks but a future investor should be aware of all risk types:
- Illiquidity. There is a possibility that early exit from this investment will take more than 1 month.
- Asymmetric information. Management and current investors have access to more internal information about the company than other market participants.
- Time uncertainty. There is no information regarding next financing round or exit strategy timeframe (IPO or M&A).
- Share dilution. The issue of additional shares by a company may reduce the value of shares of existing investors.
Invest in Ginkgo Bioworks
Please, log in or sign up to invest in Ginkgo Bioworks